SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed on February 8, 2023, covering events occurring on February 3, 2023. The registrant is BioSig Technologies, Inc., a Delaware corporation trading on the NASDAQ Capital Market under the symbol BSGM. The filing discloses the entry into a material definitive agreement for a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing details a "February PIPE" transaction rather than standard periodic financial results. Key metrics from this transaction include:
- Aggregate Consideration: $1,366,994.90 raised from institutional and accredited investors.
- Common Stock Sold: 1,591,750 shares at a purchase price of $0.8588 per share.
- Warrants Issued: Warrants to purchase up to 795,875 shares at an exercise price of $0.7963 per share.
- Warrant Terms: Exercisable six months after issuance; expire five and one-half years after issuance.
- Previous Transaction (January PIPE): The filing references a prior January 10, 2023, transaction raising $1,254,884.28 for 2,178,316 shares at $0.57608 per share.
Material Changes and Unregistered Sales
The primary material change is the issuance of unregistered equity securities under Section 4(a)(2) and Regulation D exemptions. Additionally, the Company issued "Laidlaw Warrants" to its engagement agent, Laidlaw & Company (UK) Ltd., as tail provisions:
- January Laidlaw Warrant: 71,214 shares at $0.51358 exercise price.
- February Laidlaw Warrant: 87,331 shares at $0.7963 exercise price.
The filing does not provide comparative financial statements, revenue, profit, or cash flow data for the reporting period.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties typical for securities purchase agreements. The transaction was executed to raise capital, implying a need for liquidity, though specific liquidity metrics are not disclosed in this text.
Investor Verification Checklist
- Verify the dilution impact of the 1,591,750 new shares and 795,875 warrant shares on existing shareholders.
- Confirm the current cash balance and burn rate to assess the runway provided by the $1.37 million raise.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for restrictive covenants.
- Check the exercise dates for the warrants (six months post-issuance) to anticipate future potential dilution.
- Validate the pricing discrepancy between the January PIPE ($0.57608) and February PIPE ($0.8588) to understand market sentiment shifts.